GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » Cost of Goods Sold

Innovent Biologics (HKSE:01801) Cost of Goods Sold : HK$1,243 Mil (TTM As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Cost of Goods Sold?

Innovent Biologics's cost of goods sold for the six months ended in Jun. 2023 was HK$552 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Jun. 2023 was HK$1,243 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Innovent Biologics's Gross Margin % for the six months ended in Jun. 2023 was 81.32%.

Cost of Goods Sold is also directly linked to Inventory Turnover. Innovent Biologics's Inventory Turnover for the six months ended in Jun. 2023 was 0.37.


Innovent Biologics Cost of Goods Sold Historical Data

The historical data trend for Innovent Biologics's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Cost of Goods Sold Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cost of Goods Sold
Get a 7-Day Free Trial 138.96 459.67 618.77 1,039.65 1,242.82

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 353.21 552.72 513.09 551.94 690.89

Innovent Biologics Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,243 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovent Biologics  (HKSE:01801) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Innovent Biologics's Gross Margin % for the six months ended in Jun. 2023 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(2954.883 - 551.938) / 2954.883
=81.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Innovent Biologics's Inventory Turnover for the six months ended in Jun. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Innovent Biologics Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovent Biologics (HKSE:01801) Business Description

Traded in Other Exchanges
Address
168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (HKSE:01801) Headlines

No Headlines